Uncategorized
July 24, 2023 / January 12, 2026 by necteromedical
Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease and improve patients’ lives, today announced that the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance for the company to initiate a prospective, multi-center, randomized clinical trial (the stAAAble Study) to evaluate the safety and efficacy of the […]
Read more »